Oligonucleotide Therapeutics Market by Type (Antisense Oligonucleotides, siRNA, Aptamers, CpG Oligonucleotides, Splice-switching oligonucleotides, microRNA mimics and inhibitors), by Application (Neurological Disorders, Oncology, Cardiometabolic Disease, Rare Genetic Disease, Ophthalmic, infectious and autoimmune diseases), by Route of Administration (Subcutaneous, Intravenous, Intrathecal, Intravitreal, intramuscular, intranasal and inhaled routes), by End User (Hospitals & Specialty Clinics, Biopharma Manufacturers, Academic & Research Institutes), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035
St. Catharines, Ontario, 13 Nov 2026 — Vectomat Insights has published a new report titled ‘Oligonucleotide Therapeutics Market by Type, Application, Route of Administration, End User, and Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035.’ The Global Oligonucleotide Therapeutics market was valued at USD 6,718.5 Mn in 2025 and is projected to reach USD 20,718.1 Mn by 2035, growing at a CAGR of 11.92% during the forecast period 2026–2035, according to Vectomat Insights.
Antisense Oligonucleotides lead with 44.0% of 2025 revenue, but the momentum has shifted to cardiometabolic disease: Ionis's June 2026 approval of Tryngolza for severe hypertriglyceridemia and Arrowhead's Redemplo launch have put RNA-targeted drugs in front of millions of patients rather than thousands.
The Global Oligonucleotide Therapeutics market stood at USD 6,718.5 Mn in 2025 and will reach USD 20,718.1 Mn by 2035, an 11.92% CAGR. Antisense Oligonucleotides hold 44.0% of revenue and Neurological Disorders are the largest application at 32.0%. North America leads with 39.76% share, while Asia Pacific grows fastest, led by South Korea's 14.1% CAGR, according to Vectomat Insights.
Key Insights Snapshot
| Metric | Value |
|---|---|
| Report Title | Global Oligonucleotide Therapeutics Market Size, Share, Growth & Forecast By Type, Application, Route of Administration, and End User, 2026–2035 |
| Base Year Market Size | USD 6,718.5 Mn (2025) |
| Forecast Market Size | USD 20,718.1 Mn (2035) |
| CAGR | 11.92% |
| Forecast Period | 2026–2035 |
| Dominant Region | North America (39.76%) |
| Fastest-Growing Region | Asia Pacific |
| Dominant Segment | Antisense Oligonucleotides (44.0%) |
| Dominant Application | Neurological Disorders |
| Report Format | |
| Publisher | Vectomat Insights |
What Pharmaceutical Leaders Need to Know About the Oligonucleotide Therapeutics Market
Pharma R&D Heads: Delivery is the new differentiator: Novartis paid about USD 12.0 billion for Avidity's muscle-targeting conjugates. If your oligonucleotide pipeline is still liver-only, this quarter's question is which extrahepatic platform to license before the valuations climb further.
Chief Commercial Officers: Cardiometabolic Disease grows at 16.19% a year, the fastest application, as Tryngolza and Redemplo enter severe hypertriglyceridemia. Launch teams built for 6,500 rare-disease patients need cardiology-scale field forces and payer contracts now.
Manufacturing & Supply Chain VPs: Biopharma Manufacturers spending grows at 17.35% a year to USD 10,779.6 Mn by 2035. With Alnylam's siRELIS plant not fully running until late 2027, booking CDMO slots at ST Pharm or Bachem early is a direct hedge against launch delays.
Hospital Neurology & Pharmacy Directors: Intrathecal revenue grows at 18.47% a year, the fastest route, and Biogen's high-dose Spinraza regimen was approved in March 2026. Lumbar-puncture capacity and infusion-suite scheduling are becoming budget lines, not afterthoughts.
Biotech Investors: Two big 2026 outcome trials missed, in ATTR cardiomyopathy and Lp(a). Programs with validated biomarker-to-outcome links, such as triglyceride lowering, now carry less risk than first-in-class outcome bets at the same stage.

What Is the Oligonucleotide Therapeutics Market?
Oligonucleotide therapeutics refers to drugs built from short synthetic strands of DNA or RNA that silence, edit or redirect the genetic message behind a disease. Why now? Because the class just crossed from ultra-rare conditions into common ones. Ionis's Tryngolza won an FDA label in June 2026 for severe hypertriglyceridemia, which affects more than 3 million Americans, and Arrowhead's Redemplo launched in November 2025. Big pharma has noticed: Novartis paid about USD 12.0 billion for Avidity in a deal announced in October 2025. For investors, the takeaway is simple. This market is no longer a rare-disease niche; it's a cardiology and neurology growth story worth USD 20,718.1 Mn by 2035.
How Is the Oligonucleotide Therapeutics Market Segmented?
Antisense drugs still bring in the most money, with 44.0% of 2025 revenue. But siRNA, at 36.0%, is growing faster and takes the top spot before 2035. The smallest type is the one to watch: splice-switching oligonucleotides and microRNA drugs grow 19.13% a year as muscle-targeted exon skippers reach regulators. By application, Neurological Disorders lead at 32.0%, while Cardiometabolic Disease grows fastest at 16.19%. Subcutaneous injection carries 51.9% of revenue. And Dyne's May 2026 filing for z-rostudirsen shows where the next approvals are coming from.
This report segments the Oligonucleotide Therapeutics market as follows:
- By Type: Antisense Oligonucleotides, siRNA, Aptamers, CpG Oligonucleotides, Splice-switching oligonucleotides, microRNA mimics and inhibitors
- By Application: Neurological Disorders, Oncology, Cardiometabolic Disease, Rare Genetic Disease, Ophthalmic, infectious and autoimmune diseases
- By Route of Administration: Subcutaneous, Intravenous, Intrathecal, Intravitreal, intramuscular, intranasal and inhaled routes
- By End User: Hospitals & Specialty Clinics, Biopharma Manufacturers, Academic & Research Institutes
- By Region: North America, Europe, Asia Pacific, Latin America, The Middle East, Africa
Browse the full Oligonucleotide Therapeutics Market report →

Which Region Leads the Oligonucleotide Therapeutics Market?
North America takes 39.76% of 2025 revenue, or USD 2,671.5 Mn, and the U.S. accounts for USD 2,096.2 Mn of it because nearly every new oligonucleotide launches there first. Europe follows with 26.07%, led by Germany at USD 489.1 Mn. Asia Pacific holds 24.1% and is the fastest-growing region, and that's not just about patients: South Korea grows 14.1% a year as ST Pharm turns the country into an oligonucleotide manufacturing hub, while Japan grows 12.2%. Latin America (5.3%), the Middle East (3.04%) and Africa (1.73%) make up the rest, with access still running through tenders and named-patient programmes.

Why Is the Oligonucleotide Therapeutics Market Growing?
Cardiometabolic Labels Reach Millions — Oligonucleotides have broken out of rare disease. Ionis's June 2026 sHTG approval for Tryngolza opens a U.S. pool of more than 3 million adults.
Rare Disease Approvals Keep Coming — Three new rare-disease oligonucleotides won FDA approval in 2025 alone, from Sanofi's Qfitlia in March to Ionis's Dawnzera in August.
Intrathecal Neurology Gains Depth — Neurology is the largest application, and Biogen's March 2026 high-dose Spinraza approval shows the franchise is still being extended.
New Manufacturing Capacity Comes Online — Alnylam is spending USD 250 million on enzymatic siRNA manufacturing, and ST Pharm just booked its largest-ever API order.
The approval of TRYNGOLZA marks an historic advance for people who have long struggled to control their dangerously high triglycerides.
What's Limiting the Oligonucleotide Therapeutics Market?
Confirmatory Trials Under Scrutiny — Sarepta's ESSENCE study missed its primary endpoint in November 2025, which puts every exon-skipping accelerated approval under a brighter light.
Outcome Trials Miss in Big Indications — Two large 2026 outcome trials missed: AstraZeneca and Ionis's Wainua in ATTR-CM in July, and Novartis and Ionis's pelacarsen in Lp(a) in September.
Costly Synthesis and Purification — Solid-phase synthesis wasn't built for prevalent diseases, and purification is now the bottleneck as demand rises.
Even with those setbacks, Vectomat Insights expects the market to triple, from USD 6,718.5 Mn in 2025 to USD 20,718.1 Mn by 2035.
What Industry Leaders Are Saying About the Oligonucleotide Therapeutics Market
While the ESSENCE study did not meet statistical significance on its primary endpoint, we believe the results demonstrated a clear treatment effect.
Today's decision from NICE will be hugely welcomed news for patients and cardiologists.
For many people, ATTR-CM affects every part of daily life, yet it is still too often overlooked or diagnosed far too late.
With limited options to lower triglycerides, people living with sHTG often face a constant and real fear that a debilitating acute pancreatitis attack could strike at any time without warning.
Report Segmentation & Scope
| Vectomat Insights | Market & Reports — Report Segmentation & Scope | |
|---|---|
| Scope Included in the Study | |
| By Type |
|
| By Application |
|
| By Route of Administration |
|
| By End User |
|
| Regional Analysis | |
| North America | The U.S., Canada, Mexico |
| Europe | Germany, France, U.K., Italy, Spain, Russia, BENELUX, Sweden, Denmark, Poland, Austria, Rest of Europe |
| Asia Pacific | China, Japan, India, South Korea, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of Asia Pacific |
| Latin America | Brazil, Argentina, Colombia, Chile, Peru, Rest of Latin America |
| The Middle East | GCC (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman), Israel, Turkey, Iran, Rest of Middle East |
| Africa | South Africa, Egypt, Nigeria, Algeria, Morocco, Rest of Africa |
| Note: The scope can be further tailored as per your specific requirement. Contact sales@vectomatinsights.com | |
Who Are the Leading Companies in the Oligonucleotide Therapeutics Market?
Key players operating in the Global Oligonucleotide Therapeutics market include Ionis Pharmaceuticals (U.S.), Alnylam Pharmaceuticals (U.S.), Sarepta Therapeutics (U.S.), Biogen (U.S.), Novartis (Switzerland), Sanofi (France), AstraZeneca (U.K.), Astellas Pharma (Japan), Nippon Shinyaku (Japan), Arrowhead Pharmaceuticals (U.S.), Wave Life Sciences (Singapore), Dyne Therapeutics (U.S.), City Therapeutics (U.S.), ST Pharm (South Korea) and Bachem (Switzerland), among others. Alnylam and Ionis set the pace, and both now run their own launches instead of licensing everything out. Big pharma is buying its way in: Novartis paid about USD 12.0 billion for Avidity's antibody-oligonucleotide conjugates. The quieter contest is in manufacturing, where ST Pharm and Bachem are adding capacity for a pipeline that's outgrowing it.
What's New in the Oligonucleotide Therapeutics Market?
March 2025 — Alnylam Pharmaceuticals: The FDA approved Amvuttra (vutrisiran) for transthyretin amyloid cardiomyopathy, the first RNAi therapeutic shown to reduce cardiovascular death, hospitalisations and urgent heart-failure visits.
October 2025 — Novartis / Avidity Biosciences: Novartis agreed to acquire Avidity Biosciences, developer of antibody-oligonucleotide conjugates for neuromuscular disease, for USD 72 per share, about USD 12.0 billion; the deal completed in February 2026.
November 2025 — Arrowhead Pharmaceuticals: The FDA approved Redemplo (plozasiran), a quarterly siRNA, to reduce triglycerides in adults with familial chylomicronemia syndrome, Arrowhead's first approved medicine.
December 2025 — Alnylam Pharmaceuticals: Alnylam committed USD 250 million to add its siRELIS enzymatic-ligation manufacturing platform to its Norton, Massachusetts facility, expected to be fully operational by late 2027.
June 2026 — Ionis Pharmaceuticals: The FDA approved Tryngolza (olezarsen) as the first therapy to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, with U.S. launch in July 2026.
September 2026 — Novartis / Ionis Pharmaceuticals: The Lp(a)HORIZON Phase 3 outcomes trial of pelacarsen missed its primary endpoint, the first major Lp(a)-lowering outcomes trial to fail.
Frequently Asked Questions
How big is the oligonucleotide therapeutics market?
The global oligonucleotide therapeutics market was worth USD 6,718.5 Mn in 2025 and is forecast to reach USD 20,718.1 Mn by 2035, an 11.92% compound annual growth rate over 2026–2035. The market roughly triples in value over the decade. Growth comes from new cardiometabolic labels, continued uptake of intrathecal neurology drugs and a steady stream of rare-disease approvals, with siRNA growing faster than antisense, according to Vectomat Insights.
Which type of oligonucleotide drug has the largest share?
Antisense Oligonucleotides hold the largest share, at 44.0% of 2025 revenue or USD 2,956.1 Mn, thanks to a broad portfolio that includes Spinraza, Wainua and Tryngolza. Aptamers hold 10.0%, CpG oligonucleotides 6.0% and splice-switching drugs 4.0% of revenue. siRNA follows at 36.0% and grows faster, at 13.76% a year, so it overtakes antisense in value before 2035, reaching USD 8,781.3 Mn, according to Vectomat Insights.
Which region leads the oligonucleotide therapeutics market?
North America leads with 39.76% of 2025 revenue, worth USD 2,671.5 Mn, and the United States alone accounts for USD 2,096.2 Mn. Most new oligonucleotide drugs launch in the U.S. first. North America's lead rests on early launches and specialist pricing. Europe holds 26.07% and Asia Pacific 24.1%, and Asia Pacific is the fastest-growing region, led by South Korea at a 14.1% CAGR, according to Vectomat Insights.
What is driving growth in oligonucleotide therapeutics?
The biggest driver is the move into common diseases. Ionis's Tryngolza was approved for severe hypertriglyceridemia in June 2026, a condition affecting more than 3 million U.S. adults, and Cardiometabolic Disease is the fastest-growing application at 16.19% a year. Cardiometabolic revenue rises from USD 1,209.3 Mn in 2025 to USD 5,423.5 Mn by 2035. New rare-disease approvals and fresh manufacturing capacity, such as Alnylam's USD 250 million siRELIS plant, add to growth, according to Vectomat Insights.
Who are the leading oligonucleotide therapeutics companies?
Leading companies include Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Sarepta Therapeutics, Biogen, Novartis, Sanofi, AstraZeneca, Astellas Pharma, Nippon Shinyaku and Arrowhead Pharmaceuticals, with specialists such as Wave Life Sciences, Dyne Therapeutics and City Therapeutics and manufacturers ST Pharm and Bachem. Large pharma also buys in, as Novartis did with Avidity for about USD 12.0 billion. Alnylam and Ionis are the two platform leaders in siRNA and antisense, according to Vectomat Insights.
What are the main risks for the oligonucleotide therapeutics market?
The main risks are clinical and industrial. Sarepta's ESSENCE confirmatory study missed its primary endpoint in November 2025, and two large 2026 outcome trials, in ATTR cardiomyopathy and Lp(a), also missed. Solid-phase synthesis and purification capacity is tight as demand rises. Pricing pressure grows as labels widen into larger populations. Even so, the market still triples from 2025 to 2035, according to Vectomat Insights.
Access the Complete Oligonucleotide Therapeutics Market Report
300+ pages | Global coverage | PDF | 2026
Contact: sales@vectomatinsights.com
About Vectomat Insights
Vectomat Insights is an independent market research firm. Our analysts build every market model in-house, from company revenues, government and regulatory data, and interviews with industry participants, and each report is reviewed by a senior analyst and fact-checked before publication.
Contact: Vectomat Insights | Email: sales@vectomatinsights.com | Website: www.vectomatinsights.com · +1 416-876-0312